16 related articles for article (PubMed ID: 30257601)
1. NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
Nacarelli T; Fukumoto T; Zundell JA; Fatkhutdinov N; Jean S; Cadungog MG; Borowsky ME; Zhang R
Cancer Res; 2020 Feb; 80(4):890-900. PubMed ID: 31857293
[TBL] [Abstract][Full Text] [Related]
2. Nuclear transport of nicotinamide phosphoribosyltransferase is cell cycle-dependent in mammalian cells, and its inhibition slows cell growth.
Svoboda P; Krizova E; Sestakova S; Vapenkova K; Knejzlik Z; Rimpelova S; Rayova D; Volfova N; Krizova I; Rumlova M; Sykora D; Kizek R; Haluzik M; Zidek V; Zidkova J; Skop V
J Biol Chem; 2019 May; 294(22):8676-8689. PubMed ID: 30975903
[TBL] [Abstract][Full Text] [Related]
3. Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase.
Oh A; Ho YC; Zak M; Liu Y; Chen X; Yuen PW; Zheng X; Liu Y; Dragovich PS; Wang W
Chembiochem; 2014 May; 15(8):1121-30. PubMed ID: 24797455
[TBL] [Abstract][Full Text] [Related]
4. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
[TBL] [Abstract][Full Text] [Related]
5. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
[TBL] [Abstract][Full Text] [Related]
6. Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic-pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitor.
Liederer BM; Berezhkovskiy LM; Dean BJ; Dinkel V; Peng J; Merchant M; Plise EG; Wong H; Liu X
Xenobiotica; 2011 Apr; 41(4):327-39. PubMed ID: 21182395
[TBL] [Abstract][Full Text] [Related]
7. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
[TBL] [Abstract][Full Text] [Related]
8. Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor.
Liederer BM; Cheong J; Chou KJ; Dragovich PS; Le H; Liang X; Ly J; Mukadam S; Oeh J; Sampath D; Wang L; Wong S
Xenobiotica; 2019 Sep; 49(9):1063-1077. PubMed ID: 30257601
[TBL] [Abstract][Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]